دورية أكاديمية
Adjuvant treatment of patients with gastrointestinal stromal tumors: stratification of patients into risk group ; АДЪЮВАНТНАЯ ТЕРАПИЯ ПАЦИЕНТОВ С ГАСТРОИНТЕСТИНАЛЬНЫМИ СТРОМАЛЬНЫМИ ОПУХОЛЯМИ: СТРАТИФИКАЦИЯ БОЛЬНЫХ ПО ГРУППАМ РИСКА
| العنوان: | Adjuvant treatment of patients with gastrointestinal stromal tumors: stratification of patients into risk group ; АДЪЮВАНТНАЯ ТЕРАПИЯ ПАЦИЕНТОВ С ГАСТРОИНТЕСТИНАЛЬНЫМИ СТРОМАЛЬНЫМИ ОПУХОЛЯМИ: СТРАТИФИКАЦИЯ БОЛЬНЫХ ПО ГРУППАМ РИСКА |
|---|---|
| المؤلفون: | A. Kornilova G., S. Mordanov V., O. Oksenyuk S., L. Kogoniya M., А. Корнилова Г., С. Морданов В., О. Оксенюк С., Л. Когония М. |
| المصدر: | Malignant tumours; № 1 (2014); 39-46 ; Злокачественные опухоли; № 1 (2014); 39-46 ; 2587-6813 ; 2224-5057 |
| بيانات النشر: | Rosoncoweb |
| سنة النشر: | 2015 |
| المجموعة: | Malignant tumours (E-Jounal) / Злокачественные опухоли |
| مصطلحات موضوعية: | gastrointestinal stromal tumors, GIST, adjuvant therapy, risk groups, imatinib, гастроинтестинальные стромальные опухоли, адъювантная терапия, группы риска, иматиниб |
| الوصف: | The experience of adjuvant treatment of patients with gastrointestinal stromal tumors (GIST) demonstrated its high efficiency, allowing to increase disease-free survival by almost 2 times. Currently, low-risk patients after radical surgical treatment need dynamic observation, patients with moderate-risk recommended to receive adjuvant treatment with imatinib for 1 year and high risk patients – for 3 years. This article presents an overview of the most important prognostic factors, the analysis of which will allow clinical oncologist to stratify patients into risk groups more accurately and thus increase the effectiveness of the targeted therapy. ; Опыт проведения адъювантной терапии больных с гастроинтестинальными стромальными опухолями (ГИСО) продемонстрировал свою высокую эффективность, позволив увеличить безрецидивную выживаемость пациентов почти в 2 раза. В настоящее время пациенты группы низкого риска после проведения радикального хирургического лечения остаются под динамическим наблюдением, больным ГИСО группы умеренного риска рекомендовано проведение адъювантной терапии иматинибом в течение 1 года, высокого риска — 3 лет. В статье представлен обзор наиболее значимых прогностических факторов, анализ которых позволит клиническому онкологу наиболее точно стратифицировать больных по группам риска и тем самым увеличить эффективность проводимой таргетной терапии. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | Russian |
| العلاقة: | https://www.malignanttumors.org/jour/article/view/5/9Test; Mazur M. T., Clark H. B. Gastric stromal tumors: Reappraisal of histogenesis. Am J Surg. Pathol. — 1983; 7: 507–519.; Sarlomo-Rikala M., Kovatich A. J., Barusevicius A. et al. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol. — l998; 11 (8): 728–34.; Miettinen M., Lasota J. Gastrointestinal stromal tumours: review on morphology, molecular pathology, prognosis, and dif ferential diagnosis. Arch Pathol Lab Med. — 2006; 130: 1466–1478.; Kawanowa K., Sakuma Y., Sakurai S. et al. High incidence of microscopic gastrointestinal stromal tumors in the stomach. Human Pathol. — 2006; 37 (12): 1527–1535.; Agaimy A., Wünsch P. H., Hofstaedter F. et al. Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations. Am J Surg Pathol. — 2007; 31 (1): 113–20.; Ng E. H., Pollock R. E., Munsell M. F. et al. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. Ann Surg. — 1992; 215 (1): 68–77.; De Matteo R., Lewis J., Leung D., et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surgery. — 2000; 231: 51–58.; Dougherty M. J., Compton C., Talbert M., Wood W. C. Sarcomas of the gastrointestinal tract. Separation into favorable and unfavorable prognostic groups by mitotic count. Ann Surg. —1991; 214 (5): 569–74.; Plaat B. E., Hollema H., Molenaar W. M. et al. Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences inclinical outcome and expression of multidrug resistance proteins. J Clin Oncol. — 2000; 18 (18): 3211–20.; Mudan S., Conlon K., Woodruff J. Salvage surgery for patients with recurrent gastrointestinal sarcoma: prognostic factors to guide patient selection. Canсer. — 2000; 88: 66–74.; Antman K., Crowley J., Balcerzak S. et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced sof t tissue and bone sarcomas. J Clin Oncol. — 1993; 11 (7): 1276–85.; Zalupski M., Metch B., Balcerzak S. et al. Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study. J Nat Cancer Inst. — 1991; 83 (13): 926–32.; Pidhorecky I., Cheney R. T., Kraybill W. G. et al. Gastrointestinal stromal tumors: current diagnosis, biologic behavior, and management. Ann Surg Oncol. — 2000; 7 (9): 705–12.; Hirota S., Isozaki K., Moriyama Y. et al. Gain-function mutations of c-kit in human gastrointestinal stromal tumors. Science. — 1998; 279: 577–580.; Kindblom L. G., Remotti H. E., Aldenborg F. et al. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenot ypic characteristics of the interstitial cells of Cajal. Am J Pathol. — 1998; 152 (5): 1259–69.; Van den Abbelle A. D. 18-FDG-PET provides early evidence of biological response to STI-571 in patients with malignant gastrointestinal stromal tumors. Proc Am Soc Clin Oncol. — 2001; 20: 362.; Van Oosterom A. T., Judson I. R., Verweij J. et al. Update of phase I study of imatinib (STI 571) in advanced soft tissue sarcomas and gastrointestinal stromal tumours: a report of the EORT C Soft Tissue and Bone Sarcoma Group. Eur. J. Cancer. — 2002; 38: 83–87.; Blackstein M. E., Corless C. L., Ballman K. V. et al. Risk assessment for tumor recurrence af ter surgical resection of localized primary gastrointestinal stromal tumor: North American Intergroup phase III trial ACOSOG Z9001. GI ASCO. — 2010: 6.; Znah W. H. Efficacy and safety of adjuvant post-surgical therapy with imatinib in patients with high risk of relapsing GIST. A SCO 2007, Abstr. 10045.; European Organisation for Research and T reatment of Cancer. EORTC 62024 study protocol. Phase III randomized study of adjuvant imatinib mesylate versus observation only in patients with completely resected localized gastrointestinal stromal tumor at intermediate- or high-risk of relapse. A vailable at: http://wwwTest. cancer.gov/clinicaltrials/EORTC-62024; Joensuu H., Eriksson M., Sundby H. K. et al. One vs three years of adjuvant imatinib for operable GIST: a randomized trial. JAMA. — 2012; 307 (12): 1265–72.; ESMO Update Clinical Practice Guidelines. Ann of Oncol. — 2012; 23, Supplement 7.; Singer S., Rubin B. P., Lux M. L. et al. Prognostic value of KIT mutation t ype, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol. — 2002; 20 (18): 3898–905.; Miettinen M., Lasota J. Gastrointestinal stromal tumors-definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch. — 2001; 438 (1): 1–12.; Guillou L., Coindre J. M. Prognostic factors in sof t tissue sarcoma in the adult. Ann Pathol. — 1997; 17 (6): 375–377.; De Matteo R. P., Gold J. S., Saran L. et al. Tumor mitotic rate, size, and location independently predict recurrence after resection of primar y gastrointestinal stromal tumor (GIST). Cancer. — 2008; 112: 608–615.; ESMO Clinical Recommendations for diagnosis, treatment and follow-up. — 2010: 147–153.; Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol. — 2008; 39 (10): 1411–1419.; Gold J. S., Gönen M., Gutiérrez A. et al. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol. — 2009; 10 (11): 1045–52.; Belev B., Brčić I., Prejac J. et al. Role of Ki-67 as a prognostic factor in gastrointestinal stromal tumors. World J Gastroenterol. — 2013; 19 (4): 523–7.; Miettinen M., El-Rifai W. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Hum Pathol. — 2002; 33: 478–483.; Miettinen M., Makhlouf H. R., Sobin L. H. et al. Gastrointestinal stromal tumors (GISTs) of the jejunum and ileum: a clinicopathologic, immunohistochemical and molecular genetic study of 906 cases prior to imatinib with longterm follow-up. Am. J Surg. Pathol. — 2006; 30: 477–489.; Miettinen M., Fetsch J. F., Sobin L. H. Gastrointestinal stromal tumors in patients with neurofibromatosis: a clinicopathologic and molecular genetic study of 45 cases. Am. J. Surg. Pathol. — 2006; 30: 90–96.; Rutkowski P., Nowecki Z., Nyckowski P. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate. J Surg Oncol. — 2006; 93: 304–311.; Tarn C., Merkel E., Canutescu A. A. Analysis of KIT mutations in sporadic and familial gastrointestinal stromal tumors: therapeutic implications through protein modeling. Clin. Cancer Res. — 2005; 11: 3668–3677.; Lasota J., Miettinen M. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Department of Soft Tissue Pathology, Armed Forces Institute of Pathology, Washington DC. USA Histopathology. — 2008: 4–16.; Никулин М. П., Стилиди И. С. Гастроинтестинальные стромальные опухоли (ГИСО). Эпидемиология, диагностика, современные подходы к лечению. Современная онкология. Экстра выпуск. — 2007: 3–50.; Benjamin R. S., Rankin C., Fletcher C. For the Sarcoma Intergroup. Phase III dose-randomized study of imatinib mesylate (ST1571) for GIST: Intergroup S0033 early results. Proc Am Soc Clin Oncol. — 2003; 22: 814.; Raut C. P., Posner M., Desai J. et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J. Clin. Oncol. — 2006; 15: 2325–31.; Miettinen M., Sobin L. H., Lasota J. Gastrointestinal stromal tumors of the stomach — a clinicopathologic, immunohistochemical and molecular genetic study of 1756 cases with long-term follow-up. Am. J. Surg. Pathol. — 2005; 29: 52–68.; Miettinen M., Lasota J. Gastrointestinal stromal tumors: definition, occurrence, pathology, differential diagnosis and molecular genetics. Pol. J. Pathol. — 2003; 54: 3–24.; Снигур П. В., Анурова О. А. Стромальные опухоли двенадцатиперстной кишки. Хирургия. — 2003; 11: 46–48.; Corless C. L., Schroeder A., Griffith D. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivit y to imatinib. J. Clin. Oncol. — 2005; 23: 5357–5364.; Daum O., Grossmann P., Vanecek T. Diagnostic morphological features of PDGFRA-mutated gastrointestinal stromal tumors: molecular genetic and histologic analysis of 60 cases of gastric gastrointestinal stromal tumors. Ann. Diagn. Pathol. — 2007; 11: 27–33.; Martin J., Poveda J., Llombart-Bosch A. Deletions affecting codons 557–558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS). J. Clin. Oncol. — 2005; 23: 6190–6198.; Hassan I., You Y. N., Shyyan R. Surgically managed gastrointestinal stromal tumors: a comparative and prognostic analysis. Ann Surg Oncol. — 2008; 15 (1): 52–9.; https://www.malignanttumors.org/jour/article/view/5Test |
| DOI: | 10.18027/2224-5057-2014-1-39-46 |
| الإتاحة: | https://doi.org/10.18027/2224-5057-2014-1-39-46Test https://www.malignanttumors.org/jour/article/view/5Test |
| حقوق: | Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access). ; Авторы, публикующие статьи в данном журнале, соглашаются на следующее:Авторы сохраняют за собой автороские права и предоставляют журналу право первой публикации работы на условиях Creative Commons Attribution License, которая позволяет другим распространять данную работу с обязательным сохранением ссылок на авторов оригинальной работы и оригинальную публикацию в этом журнале.Авторы имеют право размещать их работу в сети Интернет (например в институтском хранилище или персональном сайте) до и во время процесса рассмотрения ее данным журналом, так как это может привести к продуктивному обсуждению и большему количеству ссылок на данную работу (См. The Effect of Open Access). |
| رقم الانضمام: | edsbas.D7E01902 |
| قاعدة البيانات: | BASE |
| DOI: | 10.18027/2224-5057-2014-1-39-46 |
|---|